Boehringer Ingelheim ubhengeze namhlanje ukuba i-US Food and Drug Administration (FDA) inike iBreakthrough Therapy Designation kunyango lwayo lophando lwenoveli, i-BI 1015550, yonyango lwe-idiopathic pulmonary fibrosis (IPF). I-BI 1015550 yi-inhibitor yomlomo, i-phosphodiesterase 4B (PDE4B) ekwaziyo ukujongana ne-pulmonary fibrosis - i-scarring engenakuguqulwa yezicubu zemiphunga ezichaphazela kakubi ukusebenza kwemiphunga - kunye nokuvutha okuhambelana nezifo eziqhubekayo ze-fibrosing interstitial lung (ILDs).
"Uphuhliso olukhawulezileyo lwe-BI 1015550 luyinxalenye ye-Boehringer Ingelheim elandelayo yonyango olunokubakho lwezifo zemiphunga ye-interstitial ezijolise ekulondolozeni ukusebenza kwemiphunga kunye nokuphucula ubomi bezigulana," utshilo uThomas Seck, MD, usekela-mongameli omkhulu, iMicimbi yezonyango kunye noLawulo, I-Boehringer Ingelheim Pharmaceuticals, Inc. “i-BI 1015550 imele i-molecule yokuqala kudidi lwe-PDE4B inhibitors efundelwa i-IPF kunye nezinye ii-ILDs eziqhubela phambili ze-fibrosing. Sakhe kwilifa lethu kwi-pulmonary fibrosis kwaye sisebenza kwinkqubela phambili yokuchongwa kunye nedatha yeklinikhi ngenjongo yokuba eli yeza inoveli linokuthi lifikelele kwizigulana ngokukhawuleza. "
INTO ONOKUYITHATHA KWELI NQAKU:
- BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function – and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs).
- We have built on our heritage in pulmonary fibrosis and are acting on the breakthrough designation and clinical data with the goal that this potential novel medicine can reach patients as soon as possible.
- “The accelerated development of BI 1015550 is part of Boehringer Ingelheim’s next wave of potential innovative treatments for interstitial lung diseases aimed at preserving lung function and improving the lives of patients,”.
